Clinical Trials Browser

NIH × Skin Neoplasms × fludarabine phosphate × Clear all

NCT01319565 2025-12-19

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Phase 2 Completed

102 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT01369875 2019-12-10

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Phase 2 Terminated

2 enrolled 8 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02111863 2017-09-19

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Terminated

6 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT01271907 2017-08-01

Drosophila-generated CTL

Phase 2 Terminated

3 enrolled 8 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT00610311 2015-10-28

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Phase 2 Terminated

3 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase 2 Completed

4 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT01369888 2015-01-27

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Phase 1/2 Terminated

3 enrolled 8 charts

Melanoma, Skin Neoplasms

NCT00513604 2013-06-03

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Phase 2 Completed

158 enrolled 14 charts

Melanoma, Melanoma, Experimental, Neoplasms, Skin Neoplasms

NCT00509496 2013-01-15

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Phase 2 Terminated

21 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT00509288 2012-12-28

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Phase 2 Completed

24 enrolled 11 charts

Melanoma, Skin Neoplasms